LTC3701944I2 - - Google Patents

Info

Publication number
LTC3701944I2
LTC3701944I2 LTPA2022508C LTPA2022508C LTC3701944I2 LT C3701944 I2 LTC3701944 I2 LT C3701944I2 LT PA2022508 C LTPA2022508 C LT PA2022508C LT PA2022508 C LTPA2022508 C LT PA2022508C LT C3701944 I2 LTC3701944 I2 LT C3701944I2
Authority
LT
Lithuania
Application number
LTPA2022508C
Other languages
Lithuanian (lt)
Original Assignee
Estetra Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra Srl filed Critical Estetra Srl
Publication of LTPA2022508I1 publication Critical patent/LTPA2022508I1/lt
Publication of LTC3701944I2 publication Critical patent/LTC3701944I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
LTPA2022508C 2015-06-18 2022-06-06 LTC3701944I2 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15172767 2015-06-18
EP16733341.8A EP3310333B1 (en) 2015-06-18 2016-06-17 Orodispersible dosage unit containing an estetrol component
PCT/EP2016/064065 WO2016203006A1 (en) 2015-06-18 2016-06-17 Orodispersible dosage unit containing an estetrol component

Publications (2)

Publication Number Publication Date
LTPA2022508I1 LTPA2022508I1 (enExample) 2022-06-27
LTC3701944I2 true LTC3701944I2 (enExample) 2023-12-27

Family

ID=53496426

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP20171407.8T LT3701944T (lt) 2015-06-18 2016-06-17 Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas
LTEP16733341.8T LT3310333T (lt) 2015-06-18 2016-06-17 Burnoje dirperguojama vaisto formą, turinti estetrolio komponentą
LTPA2022508C LTC3701944I2 (enExample) 2015-06-18 2022-06-06

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP20171407.8T LT3701944T (lt) 2015-06-18 2016-06-17 Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas
LTEP16733341.8T LT3310333T (lt) 2015-06-18 2016-06-17 Burnoje dirperguojama vaisto formą, turinti estetrolio komponentą

Country Status (42)

Country Link
US (4) US11147771B2 (enExample)
EP (2) EP3310333B1 (enExample)
JP (2) JP6866560B2 (enExample)
KR (2) KR102735893B1 (enExample)
CN (2) CN116077455A (enExample)
AU (4) AU2016280858B2 (enExample)
BR (1) BR112017027229B1 (enExample)
CA (1) CA2988495C (enExample)
CL (1) CL2017003209A1 (enExample)
CO (1) CO2017012670A2 (enExample)
CR (1) CR20180041A (enExample)
CU (1) CU24504B1 (enExample)
CY (2) CY1123006T1 (enExample)
DK (2) DK3310333T3 (enExample)
DO (1) DOP2017000294A (enExample)
EA (2) EA202090984A1 (enExample)
EC (1) ECSP17085659A (enExample)
ES (2) ES2906228T3 (enExample)
GE (1) GEP20217243B (enExample)
HR (2) HRP20211968T1 (enExample)
HU (3) HUE049232T2 (enExample)
IL (1) IL256282B (enExample)
LT (3) LT3701944T (enExample)
MA (1) MA45972B1 (enExample)
MD (1) MD3310333T2 (enExample)
ME (1) ME03728B (enExample)
MX (1) MX384904B (enExample)
MY (1) MY186164A (enExample)
NO (1) NO2022020I1 (enExample)
NZ (2) NZ776452A (enExample)
PE (2) PE20180522A1 (enExample)
PH (1) PH12017502326A1 (enExample)
PL (2) PL3701944T3 (enExample)
PT (2) PT3701944T (enExample)
RS (2) RS62844B1 (enExample)
SI (2) SI3701944T1 (enExample)
SM (2) SMT202000251T1 (enExample)
SV (1) SV2017005596A (enExample)
TN (1) TN2017000497A1 (enExample)
UA (1) UA123099C2 (enExample)
WO (1) WO2016203006A1 (enExample)
ZA (1) ZA201708286B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266514A (zh) 2011-06-01 2017-10-20 埃斯特拉私人有限责任公司 用于产生雌四醇中间体的方法
SI2714712T1 (sl) 2011-06-01 2016-11-30 Estetra S.P.R.L. Postopek za proizvodnjo intermediatov estetrola
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US10888518B2 (en) 2015-06-18 2021-01-12 Estetra Sprl Orodispersible tablet containing estetrol
JP6863547B2 (ja) 2015-06-18 2021-04-21 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
JP2023543953A (ja) 2020-09-29 2023-10-18 ミリセント・ファーマ・リミテッド 口腔内分散性配合物
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4243602A4 (en) 2020-11-16 2024-11-13 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
CL2021001762A1 (es) * 2021-07-01 2022-01-21 Univ Pontificia Catolica Chile Uso del estetrol como tratamiento para la endometriosis

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
CA1306950C (en) 1987-04-10 1992-09-01 Alec D. Keith Buccal administration of estrogens
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
GB2228412B (en) 1989-02-28 1993-04-14 Syntex Inc Nicardipine pharmaceutical composition for parenteral administration
JPH03237557A (ja) 1990-02-14 1991-10-23 Oki Electric Ind Co Ltd ニューラルネットワークシミュレータ及び計算機システム
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5468736A (en) 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
AU2103495A (en) 1994-08-04 1996-03-04 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
IL136831A0 (en) 1997-12-19 2001-06-14 Smithkline Beecham Corp Process for manufacturing bite-dispersion tablets
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
CA2390226A1 (en) 1999-12-02 2001-06-07 Akzo Nobel N.V. 14,15-beta-methylene substituted androgens
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1611892B1 (en) 2000-01-18 2009-09-09 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical compositions comprising drospirenone
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
DE60217324T2 (de) * 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
TR200400183T4 (tr) 2001-05-23 2004-02-23 Pantarhei Bioscience B.V. Hormonal kontrasepsiyon için vasıta ve metot
EP1390041B1 (en) 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
PT1390042E (pt) 2001-05-23 2008-03-10 Pantarhei Bioscience Bv Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
CA2448270A1 (en) 2001-05-23 2002-11-28 Panterhei Bioscience B.V. Means and method for hormonal contraception
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ES2278925T3 (es) 2001-11-15 2007-08-16 Pantarhei Bioscience B.V. Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal.
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
IL163579A0 (en) 2002-02-21 2005-12-18 Schering Ag Pharmaceutical compositions comprising one or moresteroids oneor more tetrahydrofolate components and vitamin B12
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
CA2489271C (en) 2002-06-11 2011-12-06 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
ES2399423T3 (es) 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
SI1526856T1 (sl) 2002-07-12 2008-04-30 Pantarhei Bioscience Bv Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
JP2005538150A (ja) 2002-08-28 2005-12-15 キャスパー，ロバート エストロゲン補充療法
CA2503549C (en) 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
AU2003278434A1 (en) 2002-11-05 2004-06-07 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
PT1562976E (pt) 2002-11-08 2010-08-12 Pantarhei Bioscience Bv Síntese do estetrol via esteróides derivados da estrona
CA2523830A1 (en) 2003-04-30 2004-11-11 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
CN100431545C (zh) 2003-05-22 2008-11-12 潘塔希生物科学股份有限公司 雌激素成分在制备用于治疗及预防肌与骨疼痛中的组合物中的应用
EP1673071A1 (en) 2003-09-29 2006-06-28 Novo Nordisk Femcare AG Improved stability of progestogen formulations
EP2295041A3 (en) 2003-09-29 2012-01-04 Novo Nordisk Femcare AG HRT formulations
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
PE20060318A1 (es) 2004-05-28 2006-06-15 Gruenenthal Chemie Forma de administracion para la contracepcion hormonal
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
SI1773292T1 (sl) 2004-07-01 2009-10-31 Lek Pharmaceuticals D.D. Hitro razgradljiva oralno disperzibilna farmacevtska oblika
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
NZ556465A (en) 2005-02-03 2010-10-29 Nycomed Pharma As Fast wet-massing method for the preparation of calcium-containing compositions
WO2006085497A1 (ja) 2005-02-09 2006-08-17 Kissei Pharmaceutical Co., Ltd. 口腔内崩壊錠
IS7724A (is) 2005-03-02 2006-09-03 Actavis Group Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
JP5268635B2 (ja) 2005-05-26 2013-08-21 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング １７β−ＨＳＤ１及びＳＴＳインヒビター
TW200738283A (en) 2005-06-29 2007-10-16 Wyeth Corp Formulations of conjugated estrogens and bazedoxifene
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
DE602007009358D1 (de) 2006-01-09 2010-11-04 Pantarhei Bioscience Bv Verfahren zur behandlung einer akuten gefässerkrankung
WO2007081206A1 (en) 2006-01-09 2007-07-19 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
MX2008011074A (es) 2006-03-02 2008-09-10 Warner Chilcott Co Inc Metodo anticonceptivo oral multifasico de ciclo prolongado.
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
WO2007146805A2 (en) 2006-06-08 2007-12-21 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
US20070286819A1 (en) * 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
KR20090029824A (ko) 2006-07-06 2009-03-23 바이엘 쉐링 파마 악티엔게젤샤프트 피임용 및 선천성 기형 위험 예방용 제약 제제
EP2086550A2 (en) 2006-11-29 2009-08-12 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
AU2007338843B2 (en) 2006-12-20 2013-05-09 Teva Women's Health, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
CN101583363B (zh) 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
US20080175908A1 (en) 2007-01-12 2008-07-24 Wyeth Tablet-in-tablet compositions
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
WO2008156365A1 (en) 2007-06-21 2008-12-24 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
US8518923B2 (en) 2007-07-19 2013-08-27 Pantarhei Bioscience B.V. Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation
FR2920311B1 (fr) 2007-08-31 2010-06-18 Galenix Innovations Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation
JP5399749B2 (ja) 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
PL2262486T3 (pl) 2008-08-01 2013-06-28 Krka Tovarna Zdravil D D Novo Mesto Kompozycja kwetiapiny
WO2010033832A2 (en) 2008-09-19 2010-03-25 Evestra, Inc. Estriol formulations
CN101780073B (zh) 2009-01-21 2013-07-03 重庆圣华曦药业股份有限公司 非布司他分散片药物及其制备方法
JP5753661B2 (ja) 2009-01-26 2015-07-22 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース水分散液を用いた湿式造粒打錠法
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
US20120077888A1 (en) 2009-03-26 2012-03-29 Royal College Of Surgeons In Ireland Orodispersible tablets
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
BRPI1011815A2 (pt) 2009-06-23 2016-03-29 Bayer Pharma AG "composição farmacêutica para a contracepção de emergência"
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
JP5945267B2 (ja) 2010-04-12 2016-07-05 ユニヴェルシテ クロード ベルナール リヨン １ 有機ケイ素ゾルの急速縮合によって得られるハイブリッド材料の製造方法
WO2011128336A1 (en) 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Very low-dosed solid oral dosage forms for hrt
EP2399904A1 (en) 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
EP2646003B1 (en) 2010-12-02 2020-06-03 Adare Pharmaceuticals, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
CL2013003435A1 (es) 2011-06-01 2014-08-01 Estetra Sprl Proceso de preparacion de intermediarios de estetrol utilizando catalizadores de paladio y grupos protectores acilantes o sililantes; y uso de dicho proceso para preparar estetrol.
SI2714712T1 (sl) 2011-06-01 2016-11-30 Estetra S.P.R.L. Postopek za proizvodnjo intermediatov estetrola
CN107266514A (zh) 2011-06-01 2017-10-20 埃斯特拉私人有限责任公司 用于产生雌四醇中间体的方法
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
KR102033187B1 (ko) 2011-07-19 2019-10-16 판타레이 바이오사이언스 비.브이. 디하이드로에피안드로스테론(ｄｈｅａ)을 함유하는 정제
RS55974B1 (sr) * 2011-08-11 2017-09-29 Estetra Sprl Upotreba estetrola kao kontraceptivnog sredstva u hitnim slučajevima
RU2633640C2 (ru) 2011-09-16 2017-10-16 Ферринг Б.В. Быстрорастворимая фармацевтическая композиция
RS55231B1 (sr) 2011-10-07 2017-02-28 Estetra Sprl Postupak proizvodnje estetrola
EP2790688B1 (en) 2011-12-13 2019-11-20 Arstat, Inc. A multiphasic contraceptive regimen for an oral formulation of progestin and estrogen
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
US9238265B2 (en) 2012-09-27 2016-01-19 General Electric Company Backstrike protection during machining of cooling features
WO2014159377A1 (en) * 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
JP6126456B2 (ja) 2013-05-17 2017-05-10 東和薬品株式会社 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠
US20140341326A1 (en) 2013-05-20 2014-11-20 Qualcomm Incorporated Channel estimation with discontinuous pilot signals
EP2999474A4 (en) 2013-05-21 2016-12-28 Predictive Therapeutics Llc THERAPEUTIC AND METHOD FOR USE
JP6254289B2 (ja) 2013-09-18 2017-12-27 クリスタル ファルマ、エセ、ア、ウＣｒｙｓｔａｌ Ｐｈａｒｍａ，Ｓ．Ａ．Ｕ． エステトロールの製造プロセス
US12274276B2 (en) 2013-10-03 2025-04-15 Altria Client Services Llc Dissolvable-chewable tablet
AU2014359195B2 (en) * 2013-12-04 2020-02-27 Galderma Research & Development Lipid microcapsules preferably comprising a lipophilic active substance and composition containing same, method for the production thereof, and use of same in dermatology and in cosmetics
SI3079671T1 (en) 2013-12-12 2018-04-30 Donesta Bioscience B.V. Oral disintegration solid dosage form containing an esterol component
WO2016023009A1 (en) 2014-08-07 2016-02-11 Wake Forest University Health Sciences Compositions and methods for clearing a biological sample
US9962395B2 (en) 2014-09-29 2018-05-08 The Regents Of The University Of California Compositions and methods for maintaining cognitive function
WO2016187269A1 (en) 2015-05-18 2016-11-24 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
JP6863547B2 (ja) 2015-06-18 2021-04-21 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
US10888518B2 (en) * 2015-06-18 2021-01-12 Estetra Sprl Orodispersible tablet containing estetrol
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
CN113750108B (zh) 2015-06-23 2025-08-19 莱昂实验室制药股份有限公司 用于过重女性患者的基于屈螺酮的避孕药
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
MY205032A (en) 2016-10-28 2024-09-28 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain
EP4140489A1 (en) 2018-02-07 2023-03-01 Estetra SRL Contraceptive composition with reduced cardiovascular effects
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
US10929286B2 (en) 2018-06-29 2021-02-23 Seagate Technology Llc Arbitrated management of a shared non-volatile memory resource
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Also Published As

Publication number Publication date
US20240238209A1 (en) 2024-07-18
CU24504B1 (es) 2021-04-07
HRP20200850T1 (hr) 2020-10-02
GEP20217243B (en) 2021-04-26
AU2016280858B2 (en) 2021-06-24
MY186164A (en) 2021-06-30
SMT202200102T1 (it) 2022-05-12
UA123099C2 (uk) 2021-02-17
CL2017003209A1 (es) 2018-04-13
SI3701944T1 (sl) 2022-04-29
CO2017012670A2 (es) 2018-03-28
SMT202000251T1 (it) 2020-07-08
EA201890085A1 (ru) 2018-05-31
EP3310333B1 (en) 2020-04-29
MD3310333T2 (ro) 2020-06-30
PL3701944T3 (pl) 2022-04-04
PH12017502326B1 (en) 2018-06-25
PE20231714A1 (es) 2023-10-23
AU2021203265B2 (en) 2023-06-08
CU20170161A7 (es) 2018-07-05
US11964055B2 (en) 2024-04-23
TN2017000497A1 (en) 2019-04-12
PH12017502326A1 (en) 2018-06-25
US11793760B2 (en) 2023-10-24
HUE057741T2 (hu) 2022-06-28
DOP2017000294A (es) 2018-02-15
AU2022283615A1 (en) 2023-02-02
EP3701944B1 (en) 2021-12-08
KR20180019697A (ko) 2018-02-26
SV2017005596A (es) 2018-06-20
WO2016203006A1 (en) 2016-12-22
AU2024201228A1 (en) 2024-03-14
MA45972B1 (fr) 2020-06-30
BR112017027229A2 (pt) 2018-08-21
DK3701944T3 (da) 2022-03-14
AU2021203265A1 (en) 2021-06-17
US11147771B2 (en) 2021-10-19
ES2800774T3 (es) 2021-01-04
JP6866560B2 (ja) 2021-04-28
PL3310333T3 (pl) 2020-07-13
PT3701944T (pt) 2022-01-11
ME03728B (me) 2021-01-20
KR102735893B1 (ko) 2024-11-29
MX2017016274A (es) 2018-06-19
IL256282A (en) 2018-02-28
BR112017027229B1 (pt) 2023-12-05
MX384904B (es) 2025-03-14
AU2022283615B2 (en) 2023-11-23
EA202090984A1 (ru) 2021-02-26
EA035687B1 (ru) 2020-07-27
CR20180041A (es) 2018-05-03
CN116077455A (zh) 2023-05-09
HUS2200027I1 (hu) 2022-07-28
LT3310333T (lt) 2020-06-25
KR20230074847A (ko) 2023-05-31
CA2988495C (en) 2022-02-08
PT3310333T (pt) 2020-06-08
US20220096385A1 (en) 2022-03-31
NZ776452A (en) 2024-11-29
LT3701944T (lt) 2022-04-11
NZ737945A (en) 2023-06-30
HUE049232T2 (hu) 2020-10-28
CN107787224A (zh) 2018-03-09
DK3310333T3 (da) 2020-06-02
ZA201708286B (en) 2024-11-27
JP7140355B2 (ja) 2022-09-21
CY1123006T1 (el) 2021-10-29
HK1254650A1 (en) 2019-07-26
RS60252B1 (sr) 2020-06-30
ECSP17085659A (es) 2018-03-31
EP3310333A1 (en) 2018-04-25
US20180169022A1 (en) 2018-06-21
US20230293442A1 (en) 2023-09-21
CA2988495A1 (en) 2016-12-22
KR102662025B1 (ko) 2024-05-02
AU2024201228B2 (en) 2025-04-24
HRP20211968T1 (hr) 2022-03-18
SI3310333T1 (sl) 2020-08-31
AU2016280858A1 (en) 2018-01-18
PE20180522A1 (es) 2018-03-14
ES2906228T3 (es) 2022-04-13
JP2018521985A (ja) 2018-08-09
CY1124878T1 (el) 2022-11-25
NO2022020I1 (no) 2022-06-07
LTPA2022508I1 (enExample) 2022-06-27
RS62844B1 (sr) 2022-02-28
JP2021098710A (ja) 2021-07-01
IL256282B (en) 2022-01-01
US12427114B2 (en) 2025-09-30
EP3701944A1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
LTC3701944I2 (enExample)
BR112017026777A2 (enExample)
BR112018003409A2 (enExample)
BR112018004427A2 (enExample)
AU2022228198B1 (enExample)
BE2015C047I2 (enExample)
BE2015C044I2 (enExample)
BR0009942B1 (enExample)
BR0009649B1 (enExample)
BR0000126B1 (enExample)
BR0000695B1 (enExample)
BR0000763F1 (enExample)
CN303065518S (enExample)
CN303064824S (enExample)
BR0001536B1 (enExample)
BR8103681Y1 (enExample)
BR0001684B1 (enExample)
CN303071241S (enExample)
CN303071323S (enExample)
BR0001810B1 (enExample)
BR0013291B1 (enExample)
BR0007747B1 (enExample)
BR0009994B1 (enExample)
BR0007834B1 (enExample)
BR0002033B1 (enExample)